Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04597918 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT04597918 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 99 participants.
The verdict
NCT04597918, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with diabetic macular edema (DME) who are treated with faricimab.
Interventions
- DRUG Faricimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2020-11-25 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04597918
The ClinicalTrials.gov registry entry for NCT04597918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Faricimab is the first listed.
NCT04597918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04597918 about?
NCT04597918 is a clinical study titled "A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab". This is an exploratory, prospective, multicenter, open-label, single-arm, interventional, Phase IIb study designed to explore the associations over time between clinical assessments, multimodal imaging assessments, aqueous humor (AH) biomarker patterns, and genetic polymorphisms in participants with...
What is the current status of trial NCT04597918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2020-11-25. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT04597918?
The interventions under investigation include: Faricimab (DRUG).
Who is sponsoring clinical trial NCT04597918?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.